G. Wells

发表

Induction of Tumor Cell Death through Targeting Tubulin and Evoking Dysregulation of Cell Cycle Regulatory Proteins by Multifunctional Cinnamaldehydes

Amrita A. Nagle, Fei-Fei Gan, Gavin Jones, 2012, PloS one.

Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids

G. Wells, F. Kozielski, N. D. Georgakopoulos, 2018, Chembiochem : a European journal of chemical biology.

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

R. Mantovani, P. Morris, D. Hochhauser, 2008, Molecular Cancer Therapeutics.

Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.

G. Wells, 2015, Biochemical Society transactions.

Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activity.

G. Wells, H. Pfister, R. Hancock, 2013, Organic & biomolecular chemistry.

Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design

Pedro J. Buigues, Andrei V. Pisliakov, E. Rosta, 2020, bioRxiv.

Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction.

Geoff Wells, Adrian Fowkes, A. Dinkova-Kostova, 2015, Journal of medicinal chemistry.

Development of Keap1-interactive small molecules that regulate Nrf2 transcriptional activity

G. Wells, N. D. Georgakopoulos, J. Gatliff, 2016 .

Novel C8-linked pyrrolobenzodiazepine (PBD)-heterocycle conjugates that recognize DNA sequences containing an inverted CCAAT box.

T. Ellis, J. Hartley, G. Wells, 2011, Bioorganic & medicinal chemistry letters.

Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads

Elias S. J. Arnér, G. Wells, Eng-Hui Chew, 2016, Oncotarget.

The C‐terminal head domain of Burkholderia pseudomallei BpaC has a striking hydrophilic core with an extensive solvent network

A. Goldman, G. Wells, Sarah A. Harris, 2022, Molecular microbiology.

Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ('quinols').

M. Stevens, G. Wells, A. Westwell, 2006, Bioorganic & medicinal chemistry letters.

Development of novel apoferritin formulations for antitumour benzothiazoles

G. Wells, T. Bradshaw, L. Turyanska, 2019, Cancer reports.

The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance.

J. Encinar, A. Cuadrado, G. Wells, 2022, Free radical biology & medicine.

Biochemical assays and biophysical tools for inhibitor identification and validation

G. Wells, H. Bertrand, A. Fowkes, 2013 .

Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer’s disease

A. I. Rojo, A. Cuadrado, J. Menéndez, 2017, Scientific Reports.

Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery

D. Scurr, G. Wells, T. Bradshaw, 2019, International journal of nanomedicine.

Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: synthesis, DNA interaction, cytotoxicity and differential cellular localization.

P. Loadman, J. Hartley, G. Wells, 2008, Bioorganic & medicinal chemistry letters.

Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode

A. Dinkova-Kostova, S. Dayalan Naidu, G. Wells, 2022, Journal of medicinal chemistry.

The physiological disposition of aerosolized 4-[(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl]-gamma -oxobenzenebutanoate (L-648,051) in rats.

G. Wells, F. Deluna, D. Tocco, 1988, Drug metabolism and disposition: the biological fate of chemicals.

An extended pyrrolobenzodiazepine-polyamide conjugate with selectivity for a DNA sequence containing the ICB2 transcription factor binding site.

P. Jackson, T. Ellis, D. Hochhauser, 2013, Journal of medicinal chemistry.

Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.

S. Haider, G. Wells, A. Schatzlein, 2022, European journal of medicinal chemistry.

Synthesis and Anti‐Inflammatory Activity of 2‐Amino‐4,5,6,7‐tetrahydrobenzo[b]thiophene‐Derived NRF2 Activators

A. Dinkova-Kostova, G. Wells, I. Gazaryan, 2022, ChemistryOpen.

Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648).

E. Stone, M. Stevens, G. Wells, 2008, Journal of medicinal chemistry.

Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.

E. Stone, M. Stevens, G. Wells, 2006, Journal of medicinal chemistry.

Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.

M. Stevens, G. Wells, Eng-Hui Chew, 2005, Journal of medicinal chemistry.

Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents.

A Seaton, G Wells, M. Stevens, 2000, Journal of medicinal chemistry.

Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives.

M. Stevens, G. Wells, A. Westwell, 2000, Bioorganic & medicinal chemistry letters.

Antitumor Benzothiazoles. Part 10. The Synthesis and Antitumor Activity of Benzothiazole Substituted Quinol Derivatives.

M. Stevens, G. Wells, A. Westwell, 2000 .

4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines.

M. Stevens, G. Wells, A. Westwell, 2003, Journal of medicinal chemistry.

The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding

D. Barlow, P. Long, G. Wells, 2018, Biochimie.

C2‐linked alkynyl poly‐ethylene glycol(PEG) adenosine conjugates as water‐soluble adenosine receptor agonists

G. Wells, A. Schatzlein, S. Bhakta, 2022, Chemical biology & drug design.

Synthesis and Biological Evaluation of a Novel C8-Pyrrolobenzodiazepine (PBD) Adenosine Conjugate. A Study on the Role of the PBD Ring in the Biological Activity of PBD-Conjugates

G. Wells, S. Bhakta, K. Fox, 2020, Molecules.

Heteroaromatic 4-arylquinols are novel inducers of nuclear factor-erythroid 2-related factor 2 (Nrf2).

G. Wells, T. Hagen, D. P. W. Wong, 2010, European journal of pharmacology.

Antitumor Quinol PMX464 Is a Cytocidal Anti-trypanosomal Inhibitor Targeting Trypanothione Metabolism*

A. Fairlamb, J. König, P. Wyatt, 2011, The Journal of Biological Chemistry.

Back Cover: 3-(2-Oxoethylidene)indolin-2-one Derivatives Activate Nrf2 and Inhibit NF-κB: Potential Candidates for Chemoprevention (ChemMedChem 8/2014)

S. Wong, J. Hayes, Amrita A. Nagle, 2014 .

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Antonio Cuadrado, A. I. Rojo, A. Cuadrado, 2019, Nature Reviews Drug Discovery.

The pharmacological regulation of cellular mitophagy.

G. Wells, M. Campanella, N. Georgakopoulos, 2017, Nature chemical biology.

The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2

A. Dinkova-Kostova, L. de la Vega, L. Torrente, 2019, bioRxiv.

3‐(2‐Oxoethylidene)indolin‐2‐one Derivatives Activate Nrf2 and Inhibit NF‐κB: Potential Candidates for Chemoprevention

S. Wong, J. Hayes, G. Wells, 2014, ChemMedChem.

A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3)

G. Parkinson, G. Wells, A. Wilderspin, 2018, Oncotarget.

PMI: A ΔΨm Independent Pharmacological Regulator of Mitophagy

G. Wells, F. Fagiani, Daniel A East, 2014, Chemistry & biology.

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease

J. Thornton, L. Partridge, D. Ivanov, 2017, PLoS genetics.

Derives d'alkyle 4-[4-(5-oxo-2, 3, 5, 11a-tetrahydro-5h-pyrrolo [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate et composes associes destines au traitement d'une maladie hyperplasique

G. Wells, P. Howard, D. Thurston, 2006 .

Transcriptome profiles of stem-like cells from primary breast cancers allow identification of ITGA7 as a predictive marker of chemotherapy response

W. E. Hughes, G. Wells, I. Carr, 2021, British Journal of Cancer.

Elucidation of thioredoxin as a molecular target for antitumor quinols.

A. Monks, C. Laughton, M. Stevens, 2005, Cancer research.

Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism

T. Mizushima, Takafumi Suzuki, Masayuki Yamamoto, 2021, Communications biology.

Synthesis of antitumour (1H-1,2,3-triazol-4-yl)-4-hydroxycyclohexa-2,5-dien-1-ones by copper-catalysed Huisgen cycloadditions.

M. Stevens, G. Wells, T. Bradshaw, 2010, Organic & biomolecular chemistry.

Atomic force microscopy—A tool for structural and translational DNA research

J. Hartley, G. Wells, Alice L. B. Pyne, 2021, APL bioengineering.

Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis

J. Menéndez, Ana Martínez, G. Wells, 2022, Journal of medicinal chemistry.

Intelligent Resolution: Integrating Cryo-EM with AI-driven Multi-resolution Simulations to Observe the SARS-CoV-2 Replication-Transcription Machinery in Action

John D. McCalpin, Rick L. Stevens, David J. Hardy, 2021, bioRxiv.

Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cellular mitophagy

G. Wells, M. Campanella, H. Bertrand, 2017, Scientific Reports.

Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction.

J. Hayes, G. Wells, S. Naz, 2012, Free radical biology & medicine.

Integrated Target‐Based and Phenotypic Screening Approaches for the Identification of Anti‐Tubercular Agents That Bind to the Mycobacterial Adenylating Enzyme MbtA

G. Wells, T. Parish, S. Bhakta, 2019, ChemMedChem.

Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.

M. Waring, C. Laughton, P. Loadman, 2006, Journal of medicinal chemistry.

Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein–protein interaction

G. Wells, A. Wilderspin, R. Hancock, 2013, Protein science : a publication of the Protein Society.

Protocol for a Steady-State FRET Assay in Cancer Chemoprevention.

G. Wells, A. Wilderspin, Marjolein Schaap, 2016, Methods in molecular biology.

Small molecule and peptide inhibitors of βTrCP and the βTrCP–NRF2 protein–protein interaction

G. Wells, U. Jaffry, 2023, Biochemical Society transactions.

The pharmacological regulation of cellular mitophagy.

G. Wells, M. Campanella, N. Georgakopoulos, 2017, Nature chemical biology.

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

A. I. Rojo, A. Cuadrado, W. Rumsey, 2019, Nature Reviews Drug Discovery.

3‐(2‐Oxoethylidene)indolin‐2‐one Derivatives Activate Nrf2 and Inhibit NF‐κB: Potential Candidates for Chemoprevention

S. Wong, J. Hayes, Amrita A. Nagle, 2014, ChemMedChem.